Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

ABSTRACT:

Purpose

Manganese porphyrins are redox-active drugs and superoxide dismutase mimics, which have been shown to chemosensitize lymphoma, a cancer which frequently occurs in dogs. This study aimed to identify critical information regarding the pharmacokinetics and toxicity of Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin, (MnTnBuOE-2-PyP⁵⁺, MnBuOE) in dogs as a prelude to a clinical trial in canine lymphoma patients.

Methods

A single-dose pharmacokinetic (PK) study in normal dogs was performed to determine the plasma half-life (t _1/2) of MnBuOE. A dose reduction study was performed to establish the maximum tolerated dose (MTD) of MnBuOE. The safety and PK of a multi-dosing protocol was assessed.

Results

Peak plasma drug concentration

SUBMITTER: Boss MK 

PROVIDER: S-EPMC5532403 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature